Back to Journals » Drug Design, Development and Therapy » Volume 13

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy

Authors Gomez-Peralta F, Abreu C

Received 10 November 2018

Accepted for publication 21 January 2019

Published 20 February 2019 Volume 2019:13 Pages 731—738

DOI https://doi.org/10.2147/DDDT.S165372

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 2

Editor who approved publication: Dr Tuo Deng


Video abstract presented by Fernando Gomez-Peralta.

Views: 94

Fernando Gomez-Peralta, Cristina Abreu

Endocrinology and Nutrition Unit, Hospital General de Segovia, Segovia, Spain

Abstract: Type 2 diabetes mellitus (T2DM) has become one of the leading causes of morbidity and mortality in developed countries. Low efficacy, weight gain, and hypoglycemia are the main pitfalls of previous treatments for T2DM. New therapies have been designed with the aim of improving the results in efficacy and quality of life. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RA) increase glucose-dependent insulin secretion, decrease gastric emptying, and reduce postprandial glucagon secretion. The last GLP-1 RA approved by the US Food and Drug Administration and European Medicines Agency was semaglutide. This review describes its pharmacology, core clinical data coming from the randomized controlled trials included in the development program, proven cardiovascular benefits, safety issues, and precautions for the use of semaglutide in special populations. Additionally, an overview of the positioning of semaglutide in T2DM therapy and practical issues regarding semaglutide initiation are offered.

Keywords: semaglutide, type 2 diabetes, pharmacological treatment, safety, clinical practice

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]